Infinium Pharmachem manufactures and markets Iodine Derivatives, APIs, and Iodination reaction-based bulk drugs. The company is based in Gujarat and has been operating since 2003. It will undertake contract research and manufacturing services (CRAMS) to offer its clients customised and fully confidential solutions. The company has built skills to expertly cater to industries such as pharmaceutical & biotech, speciality & performance chemicals, agrochemicals, human & animal health, cosmetics, sanitation, electrical, electronics etc.
The company caters to 250 plus clients globally across 15+ countries. Its product suite contains 200+ Iodine Derivatives and 7+ APIs.
Infinium Pharmachem IPO worth Rs.25.31 crore from 1,875,000 equity shares will open for subscription on March 31, 2023. The fixed issue IPO will be available in the price band of Rs. 135 per share with 1000 shares a lot.
Infinium Pharmachem Ltd. IPO Objective
- The company will spend the net proceed from the IPO for marketing and branding expenses
- To meet incremental working capital requirement
- Repay some of the existing market borrowings
- To meet public issue expenses
Should you invest in Infinium Pharmachem Ltd.?
These are the top reasons to consider investing in Infinium Pharmachem Ltd.
- Iodine is a critical element in human nutrition. The increasing rate of iodine deficiency in adults is a global problem and further boosts the market for iodine derivatives.
- The iodine derivative market in India is expected to hit a 6% CAGR.
- The company has a robust product suite of 200+ Iodine Derivatives and 7+ APIs.
- The company possesses strong R&D skills.
- A strong network of quality raw material suppliers helps the company bypass several supply chain bottlenecks.
Infinium Pharmachem Ltd. Noteworthy highlights
- Infinium Pharmachem would gain as the Iodine Derivatives and API markets grow domestically and internationally.
- The global iodine derivative market was valued at $659.5 million and is projected to reach $970.5 million by 2030, growing at 4.38% CAGR from 2023-2030.
- The company belongs to India’s pharmaceutical sector, currently valued at $50 billion.
Infinium Pharmachem Company Financials
| Particulars | Year ending on March 31, 2022 (₹ Lakh) | Year ending on March 31, 2021 (₹ Lakh) |
|---|---|---|
| Revenue from Operations | 7,403.77 | 5,455.79 |
| Profit After Tax (PAT) | 550.34 | 271.94 |
| EBITDA | 1096.60 | 557.60 |
| EPS | 60.07 | 26.80 |
| Period Ended | As on March 31, 2022 (₹ Lakh) | As on March 31, 2021 (₹ Lakh) |
| Current Asset | 3,393.30 | 2,231.01 |
| Current Liabilities | 2,288.31 | 1,796.98 |
Know before investing
Strengths
3The company has built long-term healthy relationships with all its clients across sectors.
A competitive research facility allows the firm to offer customised solutions to clients and meet their demands timely.
The company is aggressively expanding its international and domestic outreach.
Risks
3Low market penetration in new markets will keep investors worried.
A sudden increase in demand for product baskets has increased the inventory and interest expenses.
The company's debt situation can be a reason to worry for future investors.
